Country: Ireland
Language: English
Source: HPRA (Health Products Regulatory Authority)
TOLTERODINE TARTRATE
McDermott Laboratories Ltd t/a Gerard Laboratories
2 Milligram
Prolonged Release Capsules
2012-03-16
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Deterodine SR 2mg prolonged-release capsules 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each 2 mg prolonged-release capsule contains 2 mg of tolterodine tartrate, equivalent to 1.368 mg of tolterodine. Excipient with known effect: Each 2 mg prolonged-release capsule contains a maximum of 68.69 mg of sucrose. For the full list of excipients see section 6.1. 3 PHARMACEUTICAL FORM Prolonged-release capsules, hard Deterodine SR 2 mg prolonged-release capsule: green opaque cap and green opaque body, hard-shell gelatin ‘size 4’capsule filled with white to off-white beads. The capsule is axially printed with MYLAN over 3402 in black ink on both the cap and body and is approximately 14.3 mm long. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Symptomatic treatment of urge incontinence and/or increased urinary frequency and urgency as may occur in patients with overactive bladder syndrome. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Posology _Adults (including the elderly)_ The recommended dose is 4 mg once daily except in patients with impaired liver function or severely impaired renal function (GFR 30 ml/min) for whom the recommended dose is 2 mg once daily (see sections 4.4 and 5.2). In case of troublesome side-effects the dose may be reduced from 4 mg to 2 mg once daily. The effect of treatment should be re-evaluated after 2-3 months (see section 5.1). _Paediatric population_ The safety and efficacy of tolterodine in children have not been established (see section 5.1). Therefore tolterodine is not recommended for children. Method of administration For oral use. The prolonged-release capsules can be taken with or without food and must be swallowed whole with a glass of water. IRISH MEDICINES BOARD ___________ Read the complete document